首頁 > 市場調查報告書 > 製藥

疫苗癌症

市場調查報告書

商品編碼

1807074

胜肽癌症疫苗的全球市場:市場機會，技術平台，臨床試驗趨勢(2030年)

Global Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030

出版日期: 2025年09月01日 | 出版商:

KuicK Research | 英文 220 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球勝肽類抗癌疫苗市場：市場機會、技術平台及臨床試驗趨勢（2030 年）報告結果及重點

全球及區域市場趨勢洞察
依來源、長度和抗原決定位特異性劃分的勝肽類抗癌疫苗
臨床試驗中的勝肽類抗癌疫苗：超過 50 種疫苗
美國在勝肽類抗癌疫苗研發領域佔主導地位：超過 20 種疫苗
全球勝肽類抗癌疫苗臨床試驗洞察：按公司、國家、階段和適應症劃分
以公司劃分的勝肽類抗癌疫苗研發技術平台洞察
綜合格局

勝肽類抗癌疫苗的需求及本報告的意義

癌症仍然是全球最常見的死亡原因之一，而目前的治療方法，例如化療和放療，通常伴隨嚴重的副作用和不一致的緩解率。在這種情況下，基於勝肽的癌症疫苗可能提供一種可行的選擇，以最小的毒性實現癌症的標靶免疫破壞。透過利用腫瘤特異性勝肽或新抗原勝肽，這些疫苗能夠產生高度特異性的T細胞應答，其精準度可媲美免疫療法，而無需細胞或病毒載體平台的複雜性。

本報告旨在滿足日益增長的市場需求，為包括生物技術公司、投資者、醫療保健規劃人員和監管機構在內的利益相關者提供有關動態癌症肽疫苗市場的實用見解。由於許多候選藥物已進入臨床試驗階段並即將商業化，因此，了解其現狀和未來方向對於做出明智的決策至關重要。

報告中包含的臨床試驗見解

本報告提供了全球50多個正在進行和已完成的臨床試驗的詳細資訊。該報告按臨床試驗階段、癌症類型、治療標靶、聯合方案、申辦方、合作方、技術許可方和地區細分了研發管線。值得注意的是，人們對靶向多個表位的多價疫苗以及與檢查點抑制劑聯合研究的勝肽疫苗的興趣日益濃厚。

在後期臨床候選藥物中，SELLAS Life Sciences 的 Garinpepimut-S 目前正在進行 AML 的 III 期臨床試驗，並且在間皮瘤治療中也顯示出良好的前景。針對非小細胞肺癌、攝護腺癌、三陰性乳癌和膠質母細胞瘤的勝肽疫苗臨床試驗也正在進行中。這些試驗涵蓋了美國、歐盟、日本、中國和韓國等多個地區，凸顯了勝肽疫苗平台的國際吸引力。

參與勝肽類癌症疫苗研發的主要公司

許多製藥和生物技術公司正在開發基於勝肽的免疫療法研發管線。主要公司包括 Scancell Holdings、SELLAS Life Sciences、ISA Pharmaceuticals、Imugene 和 BrightPath Biotherapeutics。所有這些公司都在研究單價和多價疫苗策略。

有些公司針對常見的腫瘤抗原，而有些公司則根據新一代定序結果設計客製化的腫瘤新抗原疫苗。其他公司，如 OncoTherapy Science 和 VAXON Biotech，正在建立針對 WT1、MAGE-A3 和 survivin 等抗原的癌症特異性產品線。

技術平台、合作與協議

勝肽類癌症疫苗市場越來越受到尖端技術平台和策略合作夥伴關係的影響。 Moditope®（Scancell）和 Twin®（IO Biotech）等專有平台是關鍵的差異化因素，可提高免疫原性和遞送效率。此類平台能夠改善抗原決定位呈現、活化免疫細胞，並最大限度地降低免疫逃脫風險。

合作如今對於產品線開發至關重要。許多公司已經與CDMO、學術機構和大型製藥公司簽署了聯合開發協議。例如，SELLAS與紀念斯隆凱特琳癌症中心合作開發其GPS疫苗，此外，還有許多公司正在與歐洲和亞洲的區域製造夥伴合作，以提高GMP生產能力。允許肽庫和免疫資訊學工具交換的許可協議也在增加。

報告展示了勝肽類癌症疫苗領域的未來發展方向

報告指出，癌症勝肽疫苗的未來前景廣闊，但競爭激烈。目前，Riavax是韓國唯一獲批的勝肽類疫苗，儘管其概念被證明有效，但其批准隨後被撤銷。然而，自那時起，該領域的科學研究已取得顯著進展，包括增強抗原發現、更有效率的患者分層以及轉向聯合療法。

該領域的命運很可能由多表位疫苗和人工智慧及大數據分析賦能的新抗原個體化治療所掌控。商業利益很可能在膠質母細胞瘤、胰臟癌和難治性未滿足需求等尚未滿足的適應症中成長。隨著監管機構為免疫療法審批提供明確的指導方針並整合真實世界數據，未來三到五年內，幾種處於後期研發階段的勝肽類疫苗或將獲得批准。

本報告以數據為依據，深入洞察肽類癌症疫苗的創新趨勢、臨床試驗進展、合作、商業化管道等，使其成為希望在該領域保持領先地位的利益相關者的必讀之作。

Global & Regional Market Trends Insight
Peptide Cancer Vaccine Classification By Source, Length & Epitope Specificity
Peptide Cancer Vaccines In Clinical Trials: > 50 Vaccines
US Dominating Peptide Cancer Vaccines Development Landscape: > 20 Vaccines
Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Country, Phase & Indication
Insight On Peptide Cancer Vaccine Development Technology Platforms By Companies
Completive Landscape

Peptide Cancer Vaccine Need & Why This Report?

Cancer remains among the most common causes of death globally, and current therapies like chemotherapy and radiation are frequently associated with serious side effects and inconsistent response rates. In such an instance, peptide based cancer vaccines could offer a viable option for targeted immune mediated cancer destruction with less toxicity. Such vaccines utilize tumor specific or neoantigenic peptides to generate extremely specific T-cell responses with the precision of immunotherapy without the intricacy of cell or viral vector platforms.

This report is aimed at filling an expanding market need by delivering stakeholders, including biotech firms, investors, healthcare planners, and regulators, with practical insights into the dynamic cancer peptide vaccine market. With a number of candidates undergoing clinical trials and nearing commercialization, insight into the current situation and future direction is necessary for intelligent decision making.

Clinical Trials Insight Included In Report

The report delivers in-depth information from more than 50 ongoing and completed clinical trials from all over the globe. It provides a breakdown of the pipeline by trial phase, cancer type, therapeutic target, and combination regimen, as well as sponsors, collaborators, technology licensors, and geographic regions. Interestingly, there is heightened interest in multivalent vaccines acting on several epitopes as well as peptide vaccines under investigation with checkpoint inhibitors.

Among the late stage clinical contenders, SELLAS Life Sciences' Galinpepimut-S is in a Phase III trial for AML and has also been active in mesothelioma. Other ongoing trials involve peptide vaccines in NSCLC, prostate cancer, triple-negative breast cancer, and glioblastoma. The trials cover a number of geographies, such as the US, EU, Japan, China, and South Korea, highlighting the international appeal of peptide vaccine platforms.

Leading Companies Engaged In R&D Of Peptide Cancer Vaccine

There are numerous biotechnology companies as well as pharmaceutical firms that are developing peptide based immunotherapy pipelines. Some of the key players are Scancell Holdings, SELLAS Life Sciences, ISA Pharmaceuticals, Imugene, and BrightPath Biotherapeutics. They are all working on both monovalent and polyvalent vaccine strategies.

Every firm has its own distinct approach; some aim at common tumor antigens, whereas others design customized neoantigen vaccines based on next-generation sequencing results. Then there are participants such as OncoTherapy Science and VAXON Biotech that are creating cancer-specific pipelines, in general, aimed at antigens such as WT1, MAGE-A3, or survivin.

Technology Platforms, Collaborations & Agreements

The peptide cancer vaccine market is more and more influenced by cutting-edge technology platforms and strategic partnerships. Exclusive platforms like Moditope(R) (Scancell) and T-win(R) (IO Biotech) are the main differentiators that improve immunogenicity and delivery efficacy. Such platforms allow improved epitope presentation, activation of immune cells, and minimizing the risk of immune escape.

Collaborations are now essential to the advancement of pipelines. Numerous companies are entering co-development deals with CDMOs, academic institutions, or bigger pharma partners. For instance, SELLAS has collaborated with Memorial Sloan Kettering for its GPS vaccine, and various companies are collaborating with regional manufacturing partners in Europe and Asia for ramping up GMP production. Licensing deals are also increasing, allowing the exchange of peptide libraries and immunoinformatics tools among partners.

Report Indicating Future Direction Of Peptide Cancer Vaccine Segment

The report suggests a very promising but competitive future for cancer peptide vaccines. Although Riavax is currently the sole peptide vaccine that has obtained market approval in South Korea, which was subsequently withdrawn, it demonstrated the validity of the concept. The science has developed considerably since, however, with enhanced antigen discovery, more efficient stratification of patients, and a move towards combination forms of therapy.

The destiny of this space will most probably be controlled by multiepitope vaccines and neoantigen personalization enabled by AI and big data analysis. Commercial interest is likely to increase in unmet need indications like glioblastoma, pancreatic cancer, and refractory NSCLC. With regulatory agencies offering clearer guidelines for immunotherapy approvals and integration of real-world data, some late-stage peptide vaccines may receive approvals in the next 3-5 years.

This report is a must read for stakeholders looking to ride the increasing tide in this space, providing data-driven insights on innovation trends, trial updates, collaborations, and commercialization channels in the landscape of peptide cancer vaccines.

1. Introduction To Peptide Cancer Vaccines

1.1 Overview & Historical Context
1.2 Peptide Based Immunotherapy In Oncology

2. Need For Peptide Cancer Vaccines

2.1 Why Peptides Are More Desirable In Cancer Immunotherapy
2.2 Peptide Vaccines vs. Traditional Cancer Vaccines
2.3 Gaps Addressed By Peptide Vaccines

3. Peptide Cancer Vaccines Mechanism Of Action

4. Classification Of Peptide Cancer Vaccines

4.1 Based On Source Of Peptides
4.2 Based on Peptide Length
4.3 Based on Epitope Specificity

5. Peptide Cancer Vaccines Development & Clinical Trends By Indication

5.1 Brain Cancer
5.2 Breast Cancer
5.3 Lung Cancer
5.4 Skin Cancers
5.5 Gastrointestinal Cancers
5.6 Gynecologic Cancers

6. Global Peptide Cancer Vaccine Market Overview

6.1 Current Market Landscape
6.2 Future Outlook & Innovation Opportunities

7. Global Peptide Cancer Vaccine Market Development Trends By Region

7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 South Korea

8. Global Peptide Cancer Vaccine Pipeline Overview

8.1 By Country
8.2 By Company
8.3 By Indication
8.4 By Phase

9. Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Country, Phase & Indication

9.1 Preclinical
9.2 Phase-I
9.3 Phase-I/II
9.4 Phase-II
9.5 Phase-III

10. Global Peptide Cancer Vaccine Market Dynamics

10.1 Key Drivers & Opportunities
10.2 Market Challenges & Limitations

11. Technology Platforms For Peptide Cancer Vaccine Development By Companies

12. Competitive Landscape

12.1 3D Medicines
12.2 BrightPath Biotherapeutics
12.3 Circio Holding
12.4 Cecava
12.5 Dx&Vx
12.6 Elicio
12.7 Evaxion
12.8 GemVax & KAEL
12.9 IO Biotech
12.10 ISA Pharmaceuticals
12.11 OncoTherapy Science
12.12 OSE Immunotherapeutics
12.13 Nouscom
12.14 Nykode Therapeutics
12.15 Scancell
12.16 SELLAS Life Sciences
12.17 Seqker Biosciences
12.18 Shionogi
12.19 Vaxon Biotech
12.20 Zelluna

簡介目錄圖表

List of Figures

Figure 1-1: Peptide Cancer Vaccine Development - Key Milestones
Figure 1-2: Personalized Peptide Vaccines Based On Neoantigens
Figure 1-3: Peptide-Based Cancer Immunotherapy Mechanism
Figure 1-4: Dual Pathway Activation Via Peptides
Figure 1-5: Peptide Delivery Technologies
Figure 1-6: Peptide Combination Therapies
Figure 1-7: Peptide Immunotherapy - Challenges vs Solutions
Figure 2-1: Benefits of Peptides in Immunotherapy
Figure 2-2: Tumor Types & Peptide Targets
Figure 2-3: Multifunctional Peptides In Immunotherapy
Figure 2-4: Peptide-Based Immunotherapies In Global Health
Figure 2-5: Antigen Loss & Immune Escape vs Multi-Epitope Vaccination
Figure 3 1: Peptide Cancer Vaccines - Mechanism Of Action
Figure 4-1: Tumor-Associated Antigen Sources
Figure 4-2: Neoantigen Generation Sources
Figure 4-3: Tumor-Associated Antigen vs. Tumor-Specific Antigen-Derived Peptide Vaccines - Microenvironment Impact
Figure 4-4: Short Peptides - Pros & Cons
Figure 4-5: Long Peptides - Pros & Cons
Figure 4-6: Short & Long Peptide Vaccines - Antigen Processing & Presentation Pathways
Figure 4-7: CD8+ T Cell Activation Functional Outcomes
Figure 4-8: CD4+ T Cell Activation Functional Outcomes
Figure 4-9: MHC Class I & II - Antigen Processing Pathways
Figure 5-1: SURVIVE Phase II (NCT05163080) Study - Initiation & Estimated Completion Year
Figure 5-2: NCI-2015-00694 Phase II (NCT02455557) Study - Initiation & Estimated Completion Year
Figure 5-3: CONNECT1906 Phase II (NCT05096481) Study - Initiation & Estimated Completion Year
Figure 5-4: PRO13110086 Phase II (NCT02358187) Study - Initiation & Estimated Completion Year
Figure 5-5: PRO12050422 Phase I (NCT01795313) Study - Initiation & Estimated Completion Year
Figure 5-6: FLAMINGO-01 Phase III (NCT05232916) Study - Initiation & Estimated Completion Year
Figure 5-7: Pro00104868 Phase I (NCT04270149) Study - Initiation & Estimated Completion Year
Figure 5-8: CTO-IUSCCC-09138 Phase I (NCT06414733) Study - Initiation & Estimated Completion Year
Figure 5-9: 16-132 Phase I (NCT02826434) Study - Initiation & Estimated Completion Year
Figure 5-10: NCI-2016-01878 Phase II (NCT03012100) Study - Initiation & Estimated Completion Year
Figure 5-11: ARTEMIA Phase III (NCT06472245) Study - Initiation & Estimated Completion Year
Figure 5-12: PNeoVCA Phase I/II (NCT05269381) Study - Initiation & Estimated Completion Year
Figure 5-13: J23120 Phase I/II (NCT05950139) Study - Initiation & Estimated Completion Year
Figure 5-14: AMPLIFY-201 Phase I (NCT04853017) Study - Initiation & Estimated Completion Year
Figure 5-15: 18-279 Phase I (NCT03929029) Study - Initiation & Estimated Completion Year
Figure 5-16: KEYNOTE-D18 Phase III (NCT05155254) Study - Initiation & Estimated Completion Year
Figure 5-17: AMPLIFY-7P Phase I/II (NCT05726864) Study - Initiation & Estimated Completion Year
Figure 5-18: OBERTO-301 Phase II (NCT05243862) Study - Initiation & Estimated Completion Year
Figure 5-19: TEDOPAM Phase II (NCT03806309) Study - Initiation & Estimated Completion Year
Figure 5-20: GO-010 Phase II/III (NCT05141721) Study - Initiation & Estimated Completion Year
Figure 5-21: AMC-099 Phase III (NCT03284866) Study - Initiation & Estimated Completion Year
Figure 5-22: SAHoWMU-CR2024-07-107 Phase II/III (NCT06341907) Study - Initiation & Estimated Completion Year
Figure 5-23: GINECO-OV244b Phase II (NCT04713514) Study - Initiation & Estimated Completion Year
Figure 6-1: Global Cancer Peptide Vaccine Market - Future Opportunities
Figure 8-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2025 Till 2030
Figure 8-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2025 Till 2030
Figure 8-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Indication, 2025 Till 2030
Figure 8-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2025 Till 2030
Figure 10-1: Global Cancer Peptide Vaccine Market - Market Drivers & Opportunities
Figure 10-2: Global Cancer Peptide Vaccine Market - Market Challenges & Limitations
Figure 11-1: Cecava - Personalized Neoepitope Peptide Vaccine Platform
Figure 11-2: IO Biotech - T-win
Figure 11-3: ISA Pharmaceuticals - SLP Technology

List of Tables

Table 2-1: Peptide Vaccines vs. Traditional Cancer Vaccines
Table 2-2: Gaps In Cancer Treatment Addressed By Peptide Vaccines
Table 4-1: Tumor-Associated Antigen vs. Tumor-Specific Antigen-Derived Peptide Vaccines
Table 4-2: Short vs Long Peptide Vaccines
Table 4-3: Short vs Long Peptide Vaccines - Ideal Candidate Use Scenarios
Table 4-4: MHC Class I vs MHC Class II Peptide Vaccines
Table 4-5: MHC-I & MHC-II Vaccines - Unique & Overlapping Features

02-2729-4219

+886-2-2729-4219